/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Vincerx Pharma Inc Share Price Today: Live Updates & Key Insights

Vincerx Pharma Inc share price today is $0.0912, up -31.58%. The stock opened at $0.118 against the previous close of $0.1333, with an intraday high of $0.1249 and low of $0.0817.

Vincerx Pharma Inc Share Price Chart

style
pb-0

Vincerx Pharma Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Vincerx Pharma Inc Share Price Performance

$0.0912 -0.3158(-31.58%) VINC at 13 Mar 2026 03:46 PM Biotechnology
Lowest Today 0.0817
Highest Today 0.1249
Today’s Open 0.118
Prev. Close 0.1333
52 Week High 19.88
52 Week Low 0.10
Day’s Range: Low 0.0817 High 0.1249
52-Week Range: Low 0.10 High 19.88
1 day return -
1 Week return -
1 month return -
3 month return -
6 month return -
1 year return -82.75
3 year return -85.93
5 year return -99.41
10 year return -

Vincerx Pharma Inc Institutional Holdings

SAGE RHINO CAPITAL LLC 1.63

Rock Springs Capital Management LP 0.85

Armistice Capital, LLC 0.54

Vanguard Institutional Extnd Mkt Idx Tr 0.27

Geode Capital Management, LLC 0.23

Fidelity Extended Market Index 0.14

Rubric Capital Management LP 0.11

UBS Group AG 0.09

HRT FINANCIAL LLC 0.06

State Street Corp 0.05

BlackRock Inc 0.05

Extended Equity Market Fund K 0.04

Fidelity Series Total Market Index 0.03

Northern Trust Corp 0.03

Fidelity Total Market Index 0.03

Renaissance Technologies Corp 0.02

Susquehanna International Group, LLP 0.02

Spartan Extended Market Index Pool E 0.02

NT Ext Equity Mkt Idx Fd - NL 0.02

Northern Trust Extended Eq Market Idx 0.01

NT Ext Equity Mkt Idx Fd - L 0.01

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.01

Spartan Total Market Index Pool E 0.01

Jane Street Group LLC 0.01

The Colony Group LLC 0.01

Vanguard U.S. Eq Idx £ Acc 0.01

Extended Equity Market Fund M 0.00

State St US Extended Mkt Indx NL Cl C 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

NT Ext Eq Mkt Indx Fd DC Lend T3 0.00

NT Ext Eq Mkt Indx Fd DC Lend T4 0.00

Morgan Stanley - Brokerage Accounts 0.00

Northern Trust Wilshire 5000 0.00

BNYM Mellon SL Market Completion UC1 0.00

SBI Securities Co Ltd 0.00

BNYM Mellon NSL Mkt Completion Fund Inst 0.00

Bank of America Corp 0.00

Goldman Sachs Group Inc 0.00

JPMorgan Chase & Co 0.00

Tower Research Capital LLC 0.00

Vincerx Pharma Inc Market Status

Strong Buy: 1

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Vincerx Pharma Inc Fundamentals

Market Cap 1.44 M

PB Ratio 0.5284

PE Ratio 0.0

Enterprise Value -3.55 M

Total Assets 8.01 M

Volume 3030669

Vincerx Pharma Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:null 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:-172996 -0.2M, FY19:null 0.0M

Annual Net worth FY23:-48850000 -48.9M, FY22:-57160000 -57.2M, FY21:-15608000 -15.6M, FY20:-10730000 -10.7M, FY19:null 0.0M

Quarterly Revenue Q3/2024:0 0.0M, Q2/2024:0 0.0M, Q1/2024:0 0.0M, Q4/2023:1314000 1.3M, Q3/2023:0 0.0M

Quarterly Profit Q3/2024:null 0.0M, Q2/2024:-270000 -0.3M, Q1/2024:-264000 -0.3M, Q4/2023:1056000 1.1M, Q3/2023:null 0.0M

Quarterly Net worth Q3/2024:-7843000 -7.8M, Q2/2024:-1808000 -1.8M, Q1/2024:-12429000 -12.4M, Q4/2023:-4950000 -5.0M, Q3/2023:-9715000 -9.7M

About Vincerx Pharma Inc & investment objective

Company Information Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.

Organisation Biotechnology

Employees 12

Industry Biotechnology

CEO Dr. Raquel E. Izumi Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow